Nykode Therapeutics ASA (NYKD) - Cash Flow Conversion Efficiency

Latest as of June 2026: -0.079x

Based on the latest financial reports, Nykode Therapeutics ASA (NYKD) has a cash flow conversion efficiency ratio of -0.079x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Nkr-6.35 Million ≈ $-667.99K USD) by net assets (Nkr80.39 Million ≈ $8.46 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Nykode Therapeutics ASA stock valuation for the company's overall valuation and market capitalisation.

Nykode Therapeutics ASA - Cash Flow Conversion Efficiency Trend (2016–2025)

This chart illustrates how Nykode Therapeutics ASA's cash flow conversion efficiency has evolved over time, based on yearly financial data.

Nykode Therapeutics ASA Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Nykode Therapeutics ASA ranked by their cash flow conversion efficiency. Explore Nykode Therapeutics ASA cash earnings quality to measure how well operating cash flow supports reported net income.

Company	Cash Flow Conversion Efficiency
BIDV Insurance Corp VN:BIC	-0.068x
India Pesticides Limited NSE:IPL	0.084x
Dynacor Gold Mines Inc. TO:DNG	0.011x
The Ruby Mills Limited NSE:RUBYMILLS	-0.049x
Shutterstock NYSE:SSTK	0.002x
Black Spade Acquisition II Co Unit NASDAQ:BSIIU	-0.002x
Companhia Energética de Brasília - CEB SA:CEBR3	0.004x
Vestel Elektronik Sanayi ve Ticaret AS IS:VESTL	0.049x

Annual Cash Flow Conversion Efficiency for Nykode Therapeutics ASA (2016–2025)

The table below shows the annual cash flow conversion efficiency of Nykode Therapeutics ASA from 2016 to 2025. View Nykode Therapeutics ASA share price for real-time trading data and today's change.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2025-12-31	Nkr91.54 Million ≈ $9.63 Million	Nkr-29.46 Million ≈ $-3.10 Million	-0.322x	+14.42%
2024-12-31	Nkr136.21 Million ≈ $14.33 Million	Nkr-51.22 Million ≈ $-5.39 Million	-0.376x	+33.35%
2023-12-31	Nkr171.26 Million ≈ $18.02 Million	Nkr-96.62 Million ≈ $-10.17 Million	-0.564x	-328.11%
2022-12-31	Nkr157.02 Million ≈ $16.52 Million	Nkr-20.69 Million ≈ $-2.18 Million	-0.132x	-2314.20%
2021-12-31	Nkr194.06 Million ≈ $20.42 Million	Nkr1.16 Million ≈ $121.54K	0.006x	-99.41%
2020-12-31	Nkr178.85 Million ≈ $18.82 Million	Nkr180.27 Million ≈ $18.97 Million	1.008x	+365.51%
2019-12-31	Nkr242.56 Million ≈ $25.52 Million	Nkr-92.08 Million ≈ $-9.69 Million	-0.380x	+15.31%
2018-12-31	Nkr140.07 Million ≈ $14.74 Million	Nkr-62.78 Million ≈ $-6.61 Million	-0.448x	-45.30%
2017-12-31	Nkr203.53 Million ≈ $21.42 Million	Nkr-62.78 Million ≈ $-6.61 Million	-0.308x	-347.33%
2016-12-31	Nkr23.19 Million ≈ $2.44 Million	Nkr-1.60 Million ≈ $-168.25K	-0.069x	--

About Nykode Therapeutics ASA

OL:NYKD Norway Biotechnology

Market Cap

$166.04 Million

Nkr1.58 Billion NOK

Market Cap Rank

#17364 Global

#147 in Norway

Share Price

Nkr4.03

Change (1 day)

+1.51%

52-Week Range

Nkr1.58 - Nkr4.99

All Time High

Nkr91.25